Adalimumab versus placebo as add-on to standard therapy for non-infectious uveitis in the United Kingdom: the ASTUTE randomised controlled trial with treatment run-in. (PubMed, EClinicalMedicine) - Oct 20, 2026 - "This multicentre, placebo-controlled randomised trial recruited adults with sight-threatening or controlled NIU requiring oral prednisolone >5 mg/day from 18 UK NHS ophthalmology departments between 29 July 2021 and 7 June 2024...Future work should identify complementary treatments for disease refractory to adalimumab. Health Technology Assessment Programme, National Institute for Health and Care Research (NIHR); Biogen International GmbH (Baar, Switzerland) provided the placebo for the trial."
Journal • Macular Edema • Ocular Inflammation • Ophthalmology • Uveitis
|
|
; Andrew D Dick; Annie Folkard; Barnaby C Reeves; Katie Pike; Kirsty Lanyon; Lucy Culliford; Mandy Lui; Nicholas A V Beare; Rachel C M Brierley; Rositsa Koleva-Kolarova; Sarah Baos; Sarah Wordsworth; Savita Madhusudhan; Srilakshmi M Sharma; Tunde Peto; Xuemin Zhu
|